Circulating tumor DNA: an important tool in precision medicine for lymphoma

References

• Diaz LA, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol Off J Am Soc Clin Oncol. 2014 Feb 20;32(6):579–586.
   PubMed Web of Science ®Google Scholar
• Lowes LE, Bratman SV, Dittamore R, et al. Circulating Tumor Cells (CTC) and Cell-Free DNA (cfDNA) workshop 2016: scientific opportunities and logistics for cancer clinical trial incorporation. Int J Mol Sci. 2016 Sep 8;17(9):1505.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Aranda V, Bardelli A, et al. Toward understanding and exploiting tumor heterogeneity. Nat Med. 2015 Aug;21(8):846–853.
   PubMed Web of Science ®Google Scholar
• Wang C, Hu J, Lu M, et al. A panel of five serum miRNAs as a potential diagnostic tool for early-stage renal cell carcinoma. Sci Rep. 2015 Jan;5(5):7610.
   PubMedGoogle Scholar
• Stroun M, Lyautey J, Lederrey C, et al. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta Int J Clin Chem. 2001 Nov;313(1–2):139–142.
   PubMed Web of Science ®Google Scholar
• Fatouros IG, Jamurtas AZ, Nikolaidis MG, et al. Time of sampling is crucial for measurement of cell-free plasma DNA following acute aseptic inflammation induced by exercise. Clin Biochem. 2010 Nov;43(16–17):1368–1370.
   PubMed Web of Science ®Google Scholar
• Anker P, Lyautey J, Lederrey C, et al. Circulating nucleic acids in plasma or serum. Clin Chim Acta Int J Clin Chem. 2001 Nov;313(1–2):143–146.
   PubMed Web of Science ®Google Scholar
• Bohers E, Viailly PJ, Dubois S, et al. Somatic mutations of cell-free circulating DNA detected by next-generation sequencing reflect the genetic changes in both germinal center B-cell-like and activated B-cell-like diffuse large B-cell lymphomas at the time of diagnosis. Haematologica. 2015 Jul;100(7):e280–284.
   PubMed Web of Science ®Google Scholar
• Camus V, Sarafan-Vasseur N, Bohers E, et al. Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2016 Sep;57(9):2171–2179.
   PubMed Web of Science ®Google Scholar
• Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001 Feb 15;61(4):1659–1665.
   PubMed Web of Science ®Google Scholar
• Armand P, Oki Y, Neuberg DS, et al. Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma. Br J Haematol. 2013 Oct;163(1):123–126.
   PubMed Web of Science ®Google Scholar
• Kurtz DM, Green MR, Bratman SV, et al. Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood. 2015 Jun 11;125(24):3679–3687.
   PubMed Web of Science ®Google Scholar
• Roschewski M, Dunleavy K, Pittaluga S, et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol. 2015 May;16(5):541–549.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Redmond D, Nie K, et al. Deep sequencing reveals clonal evolution patterns and mutation events associated with relapse in B-cell lymphomas. Genome Biol. 2014 Aug 15;15(8):432.
   PubMed Web of Science ®Google Scholar
• Rizzo D, Viailly P-J, Mareschal S, et al. Oncogenic events rather than antigen selection pressure may be the main driving forces for relapse in diffuse large B-cell lymphomas. Am J Hematol. 2016 Oct 13;92(1):68–76.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Nie K, Redmond D, et al. VDJ-seq: deep sequencing analysis of rearranged immunoglobulin heavy chain gene to reveal Clonal evolution patterns of B cell lymphoma. J Vis Exp JoVE. 2015 Dec;28(106):e53215.
   Google Scholar
• Leithäuser F, Bäuerle M, Huynh MQ, et al. Isotype-switched immunoglobulin genes with a high load of somatic hypermutation and lack of ongoing mutational activity are prevalent in mediastinal B-cell lymphoma. Blood. 2001 Nov 1;98(9):2762–2770.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000 Feb 3;403(6769):503–511.
   PubMed Web of Science ®Google Scholar
• Compagno M, Lim WK, Grunn A, et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature. 2009 Jun 4;459(7247):717–721.
   PubMed Web of Science ®Google Scholar
• Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010 Jan 7;463(7277):88–92.
   PubMed Web of Science ®Google Scholar
• Bohers E, Mareschal S, Bouzelfen A, et al. Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma. Genes Chromosomes Cancer. 2014 Feb;53(2):144–153.
   PubMed Web of Science ®Google Scholar
• Dubois S, Mareschal S, Picquenot J-M, et al. Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy? Oncotarget. 2015 Jun 30;6(18):16712–16724.
   PubMed Web of Science ®Google Scholar
• Mareschal S, Dubois S, Viailly P-J, et al. Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma. Genes Chromosomes Cancer. 2016 Mar;55(3):251–267.
   PubMed Web of Science ®Google Scholar
• Dubois S, Viailly P-J, Mareschal S, et al. Next-generation sequencing in diffuse large B-cell lymphoma highlights molecular divergence and Therapeutic Opportunities: a LYSA Study. Clin Cancer Res Off J Am Assoc Cancer Res. 2016 Jun 15;22(12):2919–2928.
   PubMed Web of Science ®Google Scholar
• Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014 May;20(5):548–554.
   PubMed Web of Science ®Google Scholar
• Scherer F, Kurtz DM, Newman AM, et al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med. 2016 Nov 9;8(364):364ra155.
   PubMed Web of Science ®Google Scholar
• Scherer F, Kurtz DM Development and validation of biopsy-free genotyping for molecular subtyping of diffuse large B-cell lymphoma. In Abstract 1089 ASH 2016; 2016 [cited 2016 Dec 31]. Available from: https://ash.confex.com/ash/2016/webprogram/Paper95362.html
   Google Scholar
• Bratman SV, Newman AM, Alizadeh AA, et al. Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq. Expert Rev Mol Diagn. 2015 Jun 3;15(6):715–719.
   PubMed Web of Science ®Google Scholar
• Kurtz DM, Scherer F, Newman AM, et al. Dynamic noninvasive genomic monitoring for outcome prediction in diffuse large B-cell lymphoma. Blood. 2015 Dec 3;126(23):130–130.
   PubMed Web of Science ®Google Scholar
• Assouline SE, Nielsen TH, Yu S, et al. Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma. Blood. 2016 Jul 14;128(2):185–194.
   PubMed Web of Science ®Google Scholar
• Rossi D, Diop F, Spaccarotella E, et al. Diffuse large B-cell lymphoma genotyping on the liquid biopsy. Blood. 2017 Jan 17.
   Google Scholar
• Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014 Feb 19;6(224):224ra24.
   PubMed Web of Science ®Google Scholar
• Goh H-G, Lin M, Fukushima T, et al. Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay. Leuk Lymphoma. 2011 May;52(5):896–904.
   PubMed Web of Science ®Google Scholar
• Hindson CM, Chevillet JR, Briggs HA, et al. Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat Methods. 2013 Oct;10(10):1003–1005.
   PubMed Web of Science ®Google Scholar
• Jardin F, Pujals A, Pelletier L, et al. Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma. Am J Hematol. 2016 Sep;91(9):923–930.
   PubMed Web of Science ®Google Scholar
• Dubois S, Mareschal S, Picquenot J-M, et al. Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy? Oncotarget. 2015 Feb 5.
   Web of Science ®Google Scholar
• McCabe MT, Ott HM, Ganji G, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012 Oct 10;492(7427):108–112.
   PubMed Web of Science ®Google Scholar
• Knutson SK, Kawano S, Minoshima Y, et al. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol Cancer Ther. 2014 Apr;13(4):842–854.
   PubMed Web of Science ®Google Scholar
• Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011 Feb 3;470(7332):115–119.
   PubMed Web of Science ®Google Scholar
• Dubois S, Viailly P-J, Bohers E, et al. Biological and clinical relevance of associated genomic alterations in MYD88 L265P and non-L265P mutated diffuse large B-cell lymphoma: analysis of 361 cases. Clin Cancer Res. May 2017;3(9):2232–2244.
   Web of Science ®Google Scholar
• Wilson WH, Young RM, Schmitz R, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med [Internet]. 2015 Jul 20 [cited 2015 Jul 21]. Available from: http://www.nature.com/doifinder/10.1038/nm.3884
   Web of Science ®Google Scholar
• Alcaide M, Yu S, Bushell K, et al. Multiplex droplet digital PCR quantification of recurrent somatic mutations in diffuse large B-cell and follicular lymphoma. Clin Chem. 2016 Sep;62(9):1238–1247.
   PubMed Web of Science ®Google Scholar
• Dugo N, Padula F, Mobili L, et al. Six consecutive false positive cases from cell-free fetal DNA testing in a single referring centre. J Prenat Med. 2014;8(1–2):31–35.
   PubMedGoogle Scholar
• Ilie M, Hofman V, Long E, et al. Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine? Ann Transl Med [Internet]. 2014 Nov [cited 2016 Dec 16];2(11): Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4245510/
   PubMedGoogle Scholar
• Punnoose EA, Atwal S, Liu W, et al. Evaluation of circulating tumor cells and circulating tumor DNA in non–small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin Cancer Res. 2012 Apr 15;18(8):2391–2401.
   PubMed Web of Science ®Google Scholar
• Murtaza M, Dawson S-J, Tsui DWY, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 2013 May 2;497(7447):108–112.
   PubMed Web of Science ®Google Scholar
• Kadam SK, Farmen M, Brandt JT. Quantitative measurement of cell-free plasma DNA and applications for detecting tumor genetic variation and promoter methylation in a clinical setting. J Mol Diagn JMD. 2012 Jul;14(4):346–356.
   PubMed Web of Science ®Google Scholar
• Bain BJ, Catovsky D. The leukaemic phase of non-Hodgkin’s lymphoma. J Clin Pathol. 1995 Mar;48(3):189–193.
   PubMedGoogle Scholar
• Sefrioui D, Perdrix A, Sarafan-Vasseur N, et al. Short report: monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer. Int J Cancer. 2015 Nov 15;137(10):2513–2519.
   PubMed Web of Science ®Google Scholar
• Sidransky D, Eschenbach AV, Tsai YC, et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science. 1991 May 3;252(5006):706–709.
   PubMed Web of Science ®Google Scholar
• Ralla B, Stephan C, Meller S, et al. Nucleic acid-based biomarkers in body fluids of patients with urologic malignancies. Crit Rev Clin Lab Sci. 2014 Aug;51(4):200–231.
   PubMed Web of Science ®Google Scholar
• Hubers AJ, Prinsen CFM, Sozzi G, et al. Molecular sputum analysis for the diagnosis of lung cancer. Br J Cancer. 2013 Aug 6;109(3):530–537.
   PubMed Web of Science ®Google Scholar
• Diehl F, Schmidt K, Durkee KH, et al. Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. Gastroenterology. 2008 Aug;135(2):489–498.
   PubMed Web of Science ®Google Scholar
• Kinde I, Bettegowda C, Wang Y, et al. Evaluation of DNA from the papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med. 2013 Jan 9;5(167):167ra4–167ra4.
   PubMed Web of Science ®Google Scholar
• Wang Y, Springer S, Zhang M, et al. Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. Proc Natl Acad Sci. 2015 Aug 4;112(31):9704–9709.
   PubMed Web of Science ®Google Scholar
• Fontanilles M, Marguet F, Bohers É, et al. Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma. Oncotarget. 2017 Jul 18;8(29):48157–48168.
   PubMed Web of Science ®Google Scholar
• Schürch CM, Federmann B, Quintanilla-Martinez L, et al. Tumor heterogeneity in lymphomas: a different breed. Pathobiology [Internet]. 2017 Jul 19 [cited 2017 Oct 1]. Available from: http://www.karger.com/Article/FullText/475530
   PubMedGoogle Scholar
• Roschewski M, Dunleavy K, Pittaluga S, et al. Comparative study of circulating tumor DNA and computerized tomography monitoring in untreated diffuse large B-cell lymphoma. Lancet Oncol. 2015 May;16(5):541–549.
   PubMed Web of Science ®Google Scholar
• Mancuso P, Calleri A, Antoniotti P, et al. If it is in the marrow, is it also in the blood? An analysis of 1,000 paired samples from patients with B-cell non-Hodgkin lymphoma. BMC Cancer. 2010 Nov 24;10:644.
   PubMed Web of Science ®Google Scholar
• Chae YK, Davis AA, Carneiro BA, et al. Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA. Oncotarget. 2016 Oct 4; 7(40): 65364–65373.
   Web of Science ®Google Scholar
• Huang A, Zhang X, Zhou S-L, et al. Detecting circulating tumor DNA in hepatocellular carcinoma patients using droplet digital PCR is feasible and reflects intratumoral heterogeneity. J Cancer. 2016;7(13):1907–1914.
   PubMed Web of Science ®Google Scholar
• Liao W, Yang H, Xu H, et al. Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing. Oncotarget. 2016 Jun 28;7(26):40481–40490.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Tateishi K, Niwa T, et al. Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas. Neuropathol Appl Neurobiol. 2016 Apr;42(3):279–290.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Aguilar A, Idbaih A, Boisselier B, et al. Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clin Cancer Res Off J Am Assoc Cancer Res. 2012 Oct 1;18(19):5203–5211.
   PubMed Web of Science ®Google Scholar
• Fukumura K, Kawazu M, Kojima S, et al. Genomic characterization of primary central nervous system lymphoma. Acta Neuropathol (Berl). 2016 Jun;131(6):865–875.
   PubMed Web of Science ®Google Scholar
• Mareschal S, Pham-Ledard A, Viailly PJ, et al. Identification of somatic mutations in primary cutaneous diffuse large B-cell Lymphoma, leg type by massive parallel sequencing. J Invest Dermatol. 2017 Sep;137(9):1984–1994.
   PubMed Web of Science ®Google Scholar
• Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood. 2003 Dec 1;102(12):3871–3879.
   PubMed Web of Science ®Google Scholar
• Bohers E, Viailly P-J, Bertrand P, et al. Combined genotype analysis of tumor and cell-free DNA by ultra-deep targeted sequencing: correlation with PET-scan imaging in a prospective cohort of diffuse large B-cell lymphoma patients. Abstract ASH. 2017. Available from : https://ash.confex.com/ash/2017/webprogram/Paper107849.html
   Google Scholar
• Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003 Sep 15;198(6):851–862.
   PubMed Web of Science ®Google Scholar
• Sarkozy C, Huet S, Carlton VE, et al. The prognostic value of clonal heterogeneity and quantitative assessment of plasma circulating clonal IG-VDJ sequences at diagnosis in patients with follicular lymphoma. Oncotarget. 2017 Jan 2;8(5):8765–8774.
   PubMed Web of Science ®Google Scholar
• Diehl V, Thomas RK, Re D. Part II: Hodgkin’s lymphoma–diagnosis and treatment. Lancet Oncol. 2004 Jan;5(1):19–26.
   PubMed Web of Science ®Google Scholar
• Schmitz R, Stanelle J, Hansmann M-L, et al. Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma. Annu Rev Pathol. 2009;4(1):151–174.
   PubMedGoogle Scholar
• Camus V, Stamatoullas A, Mareschal S, et al. Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma. Haematologica. 2016 Sep;101(9):1094–1101.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Fanale MA, Kwak LW, et al. Detection of classical hodgkin lymphoma in peripheral blood using high-throughput sequencing assay. Blood. 2013 Nov 15;122(21):627–627.
   PubMed Web of Science ®Google Scholar
• Primerano S, Burnelli R, Carraro E, et al. Kinetics of circulating plasma cell-free DNA in paediatric classical hodgkin lymphoma. J Cancer. 2016;7(4):364–366.
   PubMed Web of Science ®Google Scholar
• Vandenberghe P, Wlodarska I, Tousseyn T, et al. Non-invasive detection of genomic imbalances in Hodgkin/Reed-Sternberg cells in early and advanced stage Hodgkin’s lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study. Lancet Haematol. 2015 février;2(2):e55–65.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Salles G, McKay P, et al. Interim report from a phase 2 multicenter study of tazemetostat, an Ezh2 inhibitor, in patients with relapsed or refractory B-cell non-hodgkin lymphomas. Hematol Oncol. 2017 Jun 1;35:24–25.
   Google Scholar
• Elshimali Y, Khaddour H, Sarkissyan M, et al. The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients. Int J Mol Sci. 2013 Sep 13;14(9):18925–18958.
   PubMed Web of Science ®Google Scholar
• Adams HJA, De Klerk JMH, Fijnheer R, et al. Residual anatomical disease in diffuse large B-cell lymphoma patients with FDG-PET-based complete response after first-line R-CHOP therapy: Does it have any prognostic value? J Comput Assist Tomogr. 2015 Oct;39(5):810–815.
   PubMed Web of Science ®Google Scholar
• Dabaja BS, Phan J, Mawlawi O, et al. Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma. Leuk Lymphoma. 2013 Dec;54(12):2631–2638.
   PubMed Web of Science ®Google Scholar
• Melani C, Roschewski M. Molecular monitoring of cell-free circulating tumor DNA in non-hodgkin lymphoma. Oncol Williston Park N. 2016 Aug;30(8):731–738, 744.
   PubMed Web of Science ®Google Scholar
• Sesques P, Johnson NA. Approach to the diagnosis and treatment of high-grade B cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements. Blood. 2016 Nov;129(3):280–288.
   PubMedGoogle Scholar
• Yamada S, Ishida Y, Matsuno A, et al. Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations. Leuk Lymphoma. 2015 Jul;56(7):2141–2145.
   PubMed Web of Science ®Google Scholar
• Orwat DE, Batalis NI. Intravascular large B-cell lymphoma. Arch Pathol Lab Med. 2012 Mar;136(3):333–338.
   PubMed Web of Science ®Google Scholar
• Rovira J, Karube K, Valera A, et al. MYD88 L265P mutations, but no other variants, identify a subpopulation of DLBCL patients of activated B-cell origin, extranodal involvement, and poor outcome. Clin Cancer Res Off J Am Assoc Cancer Res. 2016 Jun 1;22(11):2755–2764.
   PubMed Web of Science ®Google Scholar